Pharma Trend
  • Pharma Trend
  • Pharma Award
    • Golden Tablet
    • Most innovative Product
    • Honorary Award
  • Pharma Ranking
  • Impressions
  • Sponsors & Partners
  • News
    • Gastroenterologists
    • Industry
    • Pain Therapists
    • Urologists

Gilead ranks 7th in Pharma Trend Ranking 2022

October 7, 2022 by Editorial staff

Gilead Sciences placed 7th in the multidisciplinary “Best Pharmaceutical Companies Germany” 2022 ranking in the category “research-based, world-leading pharmaceutical companies by sales”. Gilead’s latest innovation is Hepcludex® for the treatment of rare delta hepatitis. The top ranks among the TOP10 international pharmaceutical companies went to Janssen-Cilag, Novartis, Bayer Vital/Jenapharm, followed by Sanofi and Pfizer.

Gilead Sciences – a leader in HIV and liver disease

Gilead Sciences, Inc. is a United States pharmaceutical and biotechnology company based in Foster City, California. The company is listed in the S&P 500. With global sales of USD 27.3 billion (2021), Gilead is one of the largest pharmaceutical companies in the world. In addition to sites in North America, Europe and Australia, Gilead has been represented in Germany since 1991 in Martinsried near Munich, where around 285 people work. In 2017, Gilead acquired Kite Pharma, a specialist in the development of innovative cancer immunotherapies such as CAR T-cell therapy. Together, Gilead and Kite employ over 14,000 people.

Gilead researches and markets therapies for viral infectious diseases such as HIV, hepatitis, influenza and COVID-19, invasive fungal infections, systemic inflammation, cardiovascular disease and cancer. The American company is known for its commitment to HIV/AIDS and hepatitis. Its portfolio includes (2021) 11 drugs against HIV, including Atripla®, Biktarvy®, Emtriva®, Truvada®.

Gilead launched the first HIV therapy in one tablet a day and the first antiretroviral drug for pre-exposure prophylaxis (PrEP). Well-known drugs against viral hepatitis include Epclusa®, Hepsera®, Sovaldi®, Vosevi®. In 2020, Hepcludex® became the first drug approved for the treatment of adults with chronic hepatitis delta virus (HDV) infection, a rare disease. Gilead has new medicines in the pipeline in all its indications (55 clinical trials at the end of 2021). The Ebola drug Remdesivir for the treatment of COVID-19 (Veklury®) experienced a renaissance.

Gilead’s sales increased by 11% to around USD 27 billion in the pandemic year 2021. Sales of Veklury® (remdesivir) alone contributed USD 5.6 billion. HIV sales were USD 16.3 billion, and oncology USD 1.25 billion. R&D accounted for USD 5.4 billion in 2021, or about 20% of sales.

In 2005, the Gilead Foundation was established with the goal of improving global health disparities.

Awards for Gilead for innovation and sustainability

Hepcludex® for the treatment of rare hepatitis D received the award “The most innovative product” as an orphan drug from the specialist group of gastroenterologists in 2021.

About the award ceremony

The awards were announced on 13 September 2022 at the Deutsches Museum in Munich. The keynote speech was given by the patron of the event, the Bavarian Minister of Health Klaus Holetschek, Bavarian State Ministry of Health and Care. The festive awards ceremony was hosted by TV presenter Tamara Sedmak (Sat 1, n-tv, N24).

Pharma Trend - The market research on innovation and sustainability

The basis for the ranking and the awards is the Pharma Trend benchmark study, which has been conducted annually in the Rx category among physicians in Germany since 2000 and since 2018 also in the OTC and Orphan Drugs categories, and since 2019 also in the Specialty Care category on behalf of the PharmaBarometer magazine (https://pharmabarometer.de/pharmabarometer/). In 2021, the study was expanded to include the categories “Diagnostics” and “Digital Health Applications”. With the expansion of Pharma Trend, companies in pharmaceuticals and medical technology are assessed on innovation and sustainability via their most important stakeholders – doctors, pharmacists and patients. This year, Pharma Trend was conducted online with 700 physicians, including allergists, general practitioners, dermatologists, gynaecologists, oncologists/haematologists, paediatricians and urologists, as well as 100 pharmacists and 600 patients.

Further information on Pharma Trend and the report volumes at https://pharma-trend.com/en/

Related posts:

  1. Gedeon Richter receives “The Most Innovative Product” award from gynaecologists for Ryeqo® and is ranked second in the Pharma Trend Ranking 2022
  2. Bencard ranks 6th in Pharma Trend Ranking 2022
  3. Daiichi Sankyo receives the “Most Innovative Product” award from oncologists for Enhertu® and is ranked 8th in the Pharma Trend Ranking 2022
  4. Exeltis wins the “Most Innovative Product” award from gynaecologists twice and is ranked 4th in the Pharma Trend Ranking 2022
Posted in: Allgemein Tagged: Ranking

Patronage

Melanie Huml, Minister of Bavarian State Ministry of Health and Care

Pharma Trend Image and Innovation Award

The survey of innovation and sustainability in pharmaceutical companies.

  • Deutsch
  • English

In the News

  • Global Solutions Take Center Stage with AHF at AIDS Conference in Rwanda July 11, 2025
  • Members of CUPE 5102 Hold Ice Cream Social to Celebrate the Workers at Red Oak Retirement Community in Kanata July 11, 2025
  • IDT Launches All-Inclusive Gene Fragments From 7 Cents Per Base With 25% Lower Turnaround Times and Next-Day Shipping Powered by Its Cutting-Edge Synthetic Biology Facility July 10, 2025
  • Nordic Cold Chain Solutions Launches Nordic Express Pack: First Cold Chain Packaging Specifically Designed and Tested for GLP-1 Medications July 10, 2025
  • Sanger Sequencing of Borrelia burgdorferi flaB Gene Paralogs Can Detect a Single Bacterium for the Diagnosis of Lyme Disease Spirochetemia, Reported Milford Molecular Diagnostics Laboratory July 10, 2025

Partners




Bio M ist Partner der Goldenen Tablette



Media Partnerships



Esanum ist Medienpartner der Goldenen Tablette







Sponsors & Partners:


ashfield
lucky7even is sponsor of Pharma Trend
Harris Interactive is partner of Pharma Trend
PharmaBarometer
Dorothea Küsters Life Science Communications
EQS-Group is sponsor of Pharma Trend
Esanum
MCC Logo
JJ Sustainability is sponsor of Pharma Trend
Healthcare Marketing Logo weiß
Bio-M
Gesdat Logo
tiny web is sponsor of Pharma Trend

Copyright © 2023 Eurecon Verlag GmbH

Imprint   |   Privacy Statement